ALB and non-small cell lung carcinoma: A recent multicenter retrospective study has developed a comprehensive scoring system that integrates CRP, LDH, ALB, dNLR and PS (named as C-PLAN index) to predict the prognosis of NSCLC patients receiving immunotherapy combined with other anti-cancer therapies (17).